Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B2037
- Development stage
- Unknown
- Lead developer
- Bostal Pharma
- Modality
- Small Molecules
- Administration
- Intramuscular
01
Overview
B2037 is a long-acting injectable (LAI) formulation of the atypical antipsychotic brexpiprazole, developed by Bostal Pharma using the 505(b)(2) regulatory pathway. It is designed for the treatment of schizophrenia and bipolar I disorder. Brexpiprazole acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. The LAI formulation is intended to improve patient adherence by providing sustained therapeutic levels through intramuscular injection, with dosing intervals such as once monthly. The program is currently in late-stage development, with the company targeting NDA registration and potential approval in 2027.
- Other names
- brexpiprazole long-acting injectablebrexpiprazole LAI
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2B (5-Hydroxytryptamine Receptor 2B)ADRA1B (α1B)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)
Beyond the preview
Go deeper on B2037.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B2037.